ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Division Spotlight
Nuclear Nonproliferation Policy
The mission of the Nuclear Nonproliferation Policy Division (NNPD) is to promote the peaceful use of nuclear technology while simultaneously preventing the diversion and misuse of nuclear material and technology through appropriate safeguards and security, and promotion of nuclear nonproliferation policies. To achieve this mission, the objectives of the NNPD are to: Promote policy that discourages the proliferation of nuclear technology and material to inappropriate entities. Provide information to ANS members, the technical community at large, opinion leaders, and decision makers to improve their understanding of nuclear nonproliferation issues. Become a recognized technical resource on nuclear nonproliferation, safeguards, and security issues. Serve as the integration and coordination body for nuclear nonproliferation activities for the ANS. Work cooperatively with other ANS divisions to achieve these objective nonproliferation policies.
Meeting Spotlight
2024 ANS Winter Conference and Expo
November 17–21, 2024
Orlando, FL|Renaissance Orlando at SeaWorld
Standards Program
The Standards Committee is responsible for the development and maintenance of voluntary consensus standards that address the design, analysis, and operation of components, systems, and facilities related to the application of nuclear science and technology. Find out What’s New, check out the Standards Store, or Get Involved today!
Latest Magazine Issues
Aug 2024
Jan 2024
Latest Journal Issues
Nuclear Science and Engineering
September 2024
Nuclear Technology
Fusion Science and Technology
August 2024
Latest News
QSA Global, Niowave to collaborate on Ac-225 production using Ra-226
QSA Global, a provider of radioisotope products, and Niowave, a Michigan-based producer of medical radioisotopes, announced that the companies will codevelop a scalable radium purification process using Niowave’s radium-226 processing technology to meet the demand for actinium-225, an alpha-emitter used in the treatment of cancer. According to the companies, the strategic partnership marks a significant advancement in the field of radiopharmaceutical technology, enhancing the supply chain for critical radioisotopes, including Ac-225.
Niowave uses a closed-loop cycle to produce high-purity Ac-225 and other alpha emitters from Ra-226 using a superconducting electron linear accelerator. According to the company’s website, the electron beam impinges on a photon converter to irradiate the Ra-226, inducing a photon-neutron reaction to Ra-225, which decays to Ac-225.
Francesco Celani, Antonio Spallone, Sandro Pace, Basilio Polichetti, Aniello Saggese, Lorella Liberatori, Vittorio di Stefano, Paolo Marini
Fusion Science and Technology | Volume 17 | Number 4 | July 1990 | Pages 718-724
Technical Notes on Cold Fusion | doi.org/10.13182/FST90-A29208
Articles are hosted by Taylor and Francis Online.
Several experiments were performed at the Gran Sasso Laboratory on an 0.8-cm-diam × 5-cm-long, hyperpure, high-temperature vacuum-annealed palladium rod used as a cathode for electrolytic infusion of D2O and 0.1 M LiOH with regular additions of gaseous CO2 at a current density of 60 mA/cm2. In the very low background radiation environment, several gamma bursts lasting up to 15 min were detected whose intensity, in terms of cold fusion, was > 10−20 fusion/(deuteron pair · s). Under normal background conditions, none of these burst signals would have been detected with statistical significance. The shape and intensity of these signals are quite similar to those detected previously.